PRTA Insider Trading

Insider Ownership Percentage: 28.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Prothena Insider Trading History Chart

This chart shows the insider buying and selling history at Prothena by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Prothena Share Price & Price History

Current Price: $11.32
Price Change: Price Decrease of -0.82 (-6.75%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for PRTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$11.32Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Prothena (NASDAQ:PRTA)

97.08% of Prothena stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PRTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$53Mbought$5.42MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Prothena logo
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More on Prothena

Today's Range

Now: $11.32
Low: $11.11
High: $11.84

50 Day Range

MA: $14.11
Low: $11.32
High: $16.04

52 Week Range

Now: $11.32
Low: $11.12
High: $25.42

Volume

456,544 shs

Average Volume

490,748 shs

Market Capitalization

$609.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Prothena?

Prothena's top insider shareholders include:
  1. Gene G Kinney (CEO)
  2. Tran Nguyen (CFO)
  3. Dennis J Selkoe (Director)
  4. Brandon S Smith (COO)
  5. Carol D Karp (Insider)
  6. Hideki Garren (Insider)
  7. Karin L Walker (CAO)
  8. Michael J Malecek (Insider)
  9. Wagner M Zago (Insider)
Learn More about top insider investors at Prothena.